We are live on ! Find out more
PIM

Partner Investment Management Portfolio holdings

AUM $13.9M
1-Year Est. Return 55.92%
This Fund
S&P 500
This Quarter Est. Return
+10.06%
1 Year Est. Return
+55.92%
3 Year Est. Return
+168.07%
5 Year Est. Return
+301.91%
10 Year Est. Return
–
AUM
$124M
AUM Growth
+$31.3M
Cap. Flow
+$17.7M
Cap. Flow %
14.26%
Top 10 Hldgs %
30.99%
Holding
124
New
34
Increased
26
Reduced
39
Closed
14

Top Buys

Rank Stock Value
1
UBX
Unity Biotechnology
UBX
+$4.51M
2
SPOT icon
Spotify
SPOT
+$1.47M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$1.31M
4
CNC icon
Centene
CNC
+$1.21M
5
APTX
Aptinyx Inc. Common Stock
APTX
+$1.17M

Top Sells

Rank Stock Value
1
ALNA
Allena Pharmaceuticals
ALNA
+$4M
2
BMY icon
Bristol-Myers Squibb
BMY
+$3.52M
3
MSFT icon
Microsoft
MSFT
+$2.51M
4
BAX icon
Baxter International
BAX
+$1.81M
5
BOX icon
Box
BOX
+$1.26M

Sector Composition

Rank Sector Weight
1 Healthcare 44.55%
2 Technology 12.71%
3 Communication Services 9.85%
4 Consumer Discretionary 3.5%
5 Financials 2.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GSKY
76
DELISTED
GreenSky, Inc. Class A Common Stock
GSKY
$452K 0.37%
+21,387
New +$513K
ECYT
77
DELISTED
Endocyte, Inc. Common Stock
ECYT
$446K 0.36%
32,345
+4,141
+15% +$49.1K
DVA icon
78
CALL
DaVita
DVA
$11.4B
$431K 0.35%
+6,200
New +$414K
IRTC icon
79
iRhythm Holdings
IRTC
$4.31B
$429K 0.35%
+5,287
New +$370K
MNK
80
PUT
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$424K 0.34%
+22,700
New +$361K
CLVS
81
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$409K 0.33%
+9,000
New +$438K
ALDR
82
DELISTED
Alder Biopharmaceuticals
ALDR
$376K 0.3%
23,796
-5,983
-20% -$90.9K
CSII
83
DELISTED
Cardiovascular Systems, Inc.
CSII
$366K 0.3%
11,329
+2,695
+31% +$74.2K
SNNA
84
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
$263K 0.21%
17,343
– –
PAGS icon
85
PagSeguro Digital
PAGS
$2.58B
$249K 0.2%
8,981
+3,880
+76% +$128K
LCI
86
CALL
DELISTED
Lannett Company, Inc.
LCI
$239K 0.19%
+4,400
New +$277K
KURA icon
87
Kura Oncology
KURA
$837M
$187K 0.15%
10,260
-958
-9% -$16.2K
CUTR
88
DELISTED
Cutera, Inc.
CUTR
$182K 0.15%
4,511
+408
+10% +$18.8K
ARAY icon
89
Accuray
ARAY
$35.5M
$173K 0.14%
42,268
-3,948
-9% -$18.3K
BOLD
90
DELISTED
Audentes Therapeutics, Inc
BOLD
$162K 0.13%
+4,233
New +$157K
CBLK
91
DELISTED
Carbon Black, Inc. Common Stock
CBLK
$160K 0.13%
+6,163
New +$159K
NITE
92
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$152K 0.12%
9,523
-889
-9% -$12.7K
SLDB icon
93
Solid Biosciences
SLDB
$851M
$134K 0.11%
+251
New +$77.2K
ANAB icon
94
AnaptysBio
ANAB
$1.66B
$121K 0.1%
1,709
+774
+83% +$64.9K
RCUS icon
95
Arcus Biosciences
RCUS
$3.59B
$64K 0.05%
5,257
-441
-8% -$6.92K
AUTL
96
Autolus Therapeutics
AUTL
$546M
$57K 0.05%
+2,126
New +$56.2K
BOX icon
97
Box
BOX
$4.55B
$48K 0.04%
1,915
-50,831
-96% -$1.26M
ZS icon
98
Zscaler
ZS
$27.3B
$45K 0.04%
1,258
-20
-2% -$610
NTGN
99
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
$32K 0.03%
+2,522
New +$34.5K
DOCU
100
DocuSign
DOCU
$11.3B
$27K 0.02%
+518
New +$26.1K
1 2 3
4
5

Similar funds

SWM
Sequoia Wealth Management Hoffman Estates, Illinois $12.9M AUM 25.75% 1-Year Est. Return
ACM
ADI Capital Management New York $17.5M AUM 49.32% 1-Year Est. Return
ECAU
Everett Capital Advisors (UK) London, United Kingdom $18.6M AUM 22.81% 1-Year Est. Return
SL
Signition LP New York $20M AUM 28.26% 1-Year Est. Return
DII
Domini Impact Investments New York $7.59M AUM 47.68% 1-Year Est. Return
FIM
FourPoints Investment Managers Paris, France $21.1M AUM 11.11% 1-Year Est. Return
EM
Emancipation Management New York $22.4M AUM 18.33% 1-Year Est. Return
BHC
Balch Hill Capital San Francisco, California $22.8M AUM

Partner Investment Management's Q2 2018 Portfolio in Review

As of Q2 2018, Partner Investment Management held 124 positions worth $124M, up 34% from $92.6M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Partner Investment Management deployed $17.7M of net new capital in Q2 2018, opening 34 new positions and adding to 26 existing holdings. Its largest new stake was Unity Biotechnology: 30,876 shares worth $4.08M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 57% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Allena Pharmaceuticals, an estimated $4M trimmed.

  • Partner Investment Management's largest Q2 2018 buy was Unity Biotechnology: 30,876 shares worth $4.08M.
  • Partner Investment Management added most to Alphabet (Google) Class A in Q2 2018, an estimated $1.12M increase.
  • Partner Investment Management's biggest Q2 2018 reduction was Allena Pharmaceuticals, cutting an estimated $4M.
  • Partner Investment Management fully exited Bristol-Myers Squibb in Q2 2018, selling an estimated $3.52M.
  • Partner Investment Management's ten largest holdings make up 31% of its $124M portfolio in Q2 2018.
  • Partner Investment Management opened 34 new positions and closed 14 in Q2 2018.
  • Partner Investment Management's portfolio value rose 34% quarter-over-quarter to $124M.

Based on Partner Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.